Graham Capital Management L.P. Acquires 15,963 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Graham Capital Management L.P. raised its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 75.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 37,102 shares of the company's stock after purchasing an additional 15,963 shares during the period. Graham Capital Management L.P. owned 0.08% of Omnicell worth $1,652,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC lifted its position in Omnicell by 51.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock valued at $35,000 after purchasing an additional 273 shares during the period. Johnson Financial Group Inc. acquired a new stake in shares of Omnicell in the 4th quarter valued at approximately $37,000. Van ECK Associates Corp raised its position in shares of Omnicell by 47.0% in the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company's stock valued at $44,000 after acquiring an additional 315 shares during the period. Headlands Technologies LLC acquired a new stake in shares of Omnicell in the 4th quarter valued at approximately $53,000. Finally, First Horizon Advisors Inc. raised its position in shares of Omnicell by 36.3% in the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock valued at $59,000 after acquiring an additional 355 shares during the period. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Omnicell Stock Down 0.4%

OMCL stock traded down $0.12 during mid-day trading on Friday, hitting $27.96. 661,695 shares of the company were exchanged, compared to its average volume of 559,392. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. The firm has a market cap of $1.31 billion, a P/E ratio of 103.56, a P/E/G ratio of 7.53 and a beta of 0.78. The firm's 50 day simple moving average is $31.41 and its 200 day simple moving average is $39.46. Omnicell, Inc. has a 1-year low of $22.66 and a 1-year high of $55.75.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported $0.26 EPS for the quarter, topping the consensus estimate of $0.16 by $0.10. The firm had revenue of $269.67 million for the quarter, compared to the consensus estimate of $260.18 million. Omnicell had a net margin of 1.13% and a return on equity of 3.82%. The business's quarterly revenue was up 9.5% on a year-over-year basis. During the same period last year, the company posted $0.03 EPS. On average, sell-side analysts predict that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. JPMorgan Chase & Co. cut their price target on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a research report on Thursday, March 20th. Benchmark cut their price target on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. StockNews.com downgraded shares of Omnicell from a "buy" rating to a "hold" rating in a research report on Saturday, May 3rd. Finally, Wells Fargo & Company upgraded shares of Omnicell from an "equal weight" rating to an "overweight" rating and increased their price target for the company from $31.00 to $35.00 in a research report on Wednesday. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $46.50.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.